Literature DB >> 11826132

Chronic morphine treatment modulates the extracellular levels of endogenous enkephalins in rat brain structures involved in opiate dependence: a microdialysis study.

Magdalena Mas Nieto1, Jodie Wilson, Annie Cupo, Bernard P Roques, Florence Noble.   

Abstract

The endogenous opioid system is often assumed to play a role in vulnerability to drug abuse. However, controversial results have been reported regarding the levels of enkephalins or preproenkephalin in neurons of rodent brains after opiate administration. The present study was performed to determine the extracellular levels of enkephalins and its physiological antagonist cholecystokinin (CCK), using in vivo microdialysis in freely moving rats after morphine-induced physical dependence or positive place conditioning. A large increase (340%) of Met-enkephalin was observed in the periaqueductal gray matter, a structure involved in morphine withdrawal syndrome, in morphine-dependent rats. No change in CCK immunoreactivity occurred in these conditions. Moreover, using the conditioning place preference paradigm, we observed for the first time opposite changes of enkephalin outflow in the nucleus accumbens (NAc). Thus, an increase in enkephalin levels was observed in rats placed in the drug-associated compartment and a decrease in the saline-paired side. These changes in opioid peptides in the NAc may reflect an "emotional state" of the animals in relation to the expectation of drug reward (reinforcing effects of morphine). Moreover, the lack of regulation in CCK outflow suggests that CCK-opioid interactions in morphine dependence involve probably post-receptor events.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11826132      PMCID: PMC6758524     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  61 in total

1.  A heroin-, but not a cocaine-expecting, self-administration state preferentially alters endogenous brain peptides.

Authors:  S L Cappendijk; Y L Hurd; I Nylander; J M van Ree; L Terenius
Journal:  Eur J Pharmacol       Date:  1999-01-22       Impact factor: 4.432

2.  Self-administration of methionine enkephalin into the nucleus accumbens.

Authors:  N E Goeders; J D Lane; J E Smith
Journal:  Pharmacol Biochem Behav       Date:  1984-03       Impact factor: 3.533

3.  Biobehavioral bases of the reinforcing properties of opiate drugs.

Authors:  C Kornetsky; G Bain
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

4.  CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat.

Authors:  X J Xu; Z Wiesenfeld-Hallin; J Hughes; D C Horwell; T Hökfelt
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

Review 5.  Naltrexone in the treatment of alcoholism: a clinical review.

Authors:  C P O'Brien; L A Volpicelli; J R Volpicelli
Journal:  Alcohol       Date:  1996 Jan-Feb       Impact factor: 2.405

6.  Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway.

Authors:  S L Ingram; C W Vaughan; E E Bagley; M Connor; M J Christie
Journal:  J Neurosci       Date:  1998-12-15       Impact factor: 6.167

7.  Dissociation of tolerance and dependence to morphine: a possible role for cholecystokinin.

Authors:  A E Panerai; L C Rovati; E Cocco; P Sacerdote; P Mantegazza
Journal:  Brain Res       Date:  1987-04-28       Impact factor: 3.252

8.  Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats.

Authors:  S S Negus; S J Henriksen; A Mattox; G W Pasternak; P S Portoghese; A E Takemori; M B Weinger; G F Koob
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

9.  Microdialysis reveals a morphine-induced increase in pallidal opioid peptide release.

Authors:  M F Olive; M Bertolucci; C J Evans; N T Maidment
Journal:  Neuroreport       Date:  1995-05-30       Impact factor: 1.837

Review 10.  Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse.

Authors:  S S O'Malley
Journal:  Alcohol Alcohol       Date:  1996-03       Impact factor: 2.826

View more
  15 in total

Review 1.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

Review 2.  Microdialysis and the neurochemistry of addiction.

Authors:  Mary M Torregrossa; Peter W Kalivas
Journal:  Pharmacol Biochem Behav       Date:  2007-09-12       Impact factor: 3.533

3.  Food-addiction scale measurement in 2 cohorts of middle-aged and older women.

Authors:  Alan J Flint; Ashley N Gearhardt; William R Corbin; Kelly D Brownell; Alison E Field; Eric B Rimm
Journal:  Am J Clin Nutr       Date:  2014-01-22       Impact factor: 7.045

4.  Blockade of morphine-induced behavioral sensitization by a combination of amisulpride and RB101, comparison with classical opioid maintenance treatments.

Authors:  L Cordonnier; M Sanchez; B P Roques; F Noble
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

5.  Rapid preconcentration for liquid chromatography-mass spectrometry assay of trace level neuropeptides.

Authors:  Ying Zhou; Omar S Mabrouk; Robert T Kennedy
Journal:  J Am Soc Mass Spectrom       Date:  2013-04-17       Impact factor: 3.109

6.  In vivo regulation of the μ opioid receptor: role of the endogenous opioid agents.

Authors:  Veronica Gonzalez-Nunez; Ada Jimenez González; Katherine Barreto-Valer; Raquel E Rodríguez
Journal:  Mol Med       Date:  2013-03-05       Impact factor: 6.354

Review 7.  Targeting endogenous mu- and delta-opioid receptor systems for the treatment of drug addiction.

Authors:  T S Shippenberg; A LeFevour; V I Chefer
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-11       Impact factor: 4.388

Review 8.  Dynorphin and its role in alcohol use disorder.

Authors:  Anushree N Karkhanis; Ream Al-Hasani
Journal:  Brain Res       Date:  2020-02-28       Impact factor: 3.252

9.  Autoantibodies against opioid or glutamate receptors are associated with changes in morphine reward and physical dependence in mice.

Authors:  Francesca Capone; Walter Adriani; Maria Shumilina; Galina Izykenova; Oleg Granstrem; Svetlana Dambinova; Giovanni Laviola
Journal:  Psychopharmacology (Berl)       Date:  2008-02-12       Impact factor: 4.530

Review 10.  A unified framework for addiction: vulnerabilities in the decision process.

Authors:  A David Redish; Steve Jensen; Adam Johnson
Journal:  Behav Brain Sci       Date:  2008-08       Impact factor: 21.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.